Current Report Filing (8-k)
October 04 2016 - 4:46PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 4, 2016
RESPIRERX
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
1-16467
|
|
33-0303583
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S
Employer
Identification
No.)
|
126
Valley Road, Suite C
Glen
Rock, New Jersey
|
|
07452
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (201) 444-4947
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ] Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
7.01 Regulation FD Disclosure.
On
September 12, 2016, RespireRx Pharmaceuticals Inc. (the “Company”) issued a press release announcing preliminary top-line
analysis of safety and efficacy data from a Phase 2A clinical trial of the Company’s proprietary ampakine compound, CX1739,
that was recently conducted at Duke University. The Company’s President and Chief Executive Officer, James S. Manuso, subsequently
made a presentation on Monday, September 12, 2016 at the Rodman & Renshaw 18th Annual Global Investment Conference, in part
discussing that data. A slide presentation was provided in connection with Dr. Manuso’s presentation.
On
October 3, 2016, the Company discovered an error in the data reported to it that the Company believes will affect the efficacy
data analysis. However, at this time, the Company does not know the extent of the effect. The safety data is expected to remain
unchanged. Accordingly, on October 4, 2016, the Company issued a press release retracting the efficacy data contained in the September
12, 2016 press release. The October 4, 2016 press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The
Rodman & Renshaw Conference slide presentation was included on the Company’s website in the ordinary course of business.
In light of this new information, the Company intends to remove that presentation from its website and to provide a new slide
presentation, both on its website and via a Current Report on Form 8-K, as soon as practical.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits.
A
list of exhibits required to be filed as part of this report is set forth in the Exhibit Index, which is presented elsewhere in
this document, and is incorporated herein by reference.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
RESPIRERX
PHARMACEUTICALS INC.
|
Date:
October 4, 2016
|
|
|
|
By:
|
/s/
James S. Manuso
|
|
|
James
S. Manuso
President
and Chief Executive Officer
|
EXHIBIT
INDEX
Exhibit
Number
|
|
Exhibit
Description
|
99.1
|
|
Press
Release dated October 4, 2016*
|
*
Furnished herewith.
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From Mar 2024 to Apr 2024
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From Apr 2023 to Apr 2024